Literature DB >> 11890994

Defining regions of loss of heterozygosity of 16q in breast cancer cell lines.

David F Callen1, Joanne Crawford, Cathy Derwas, Anne-Marie Cleton-Jansen, Cees J Cornelisse, Elizabeth Baker.   

Abstract

The loss of heterozygosity (LOH) of chromosome 16 was assessed in 21 breast cancer cell lines and two nontumorigenic breast epithelial cell lines by typing microsatellite markers distributed on this chromosome. In addition, dual-color fluorescence in situ hybridization was used to metaphase spreads of these cell lines using chromosome 16 paint and region specific probes. Eleven of the cell lines had LOH for chromosome 16, two for the entire chromosome, three for the long arm, and six had LOH for restricted regions of the long arm. The results supported evidence that there are two predominant regions of LOH, 16q22.1 and 16q24.3. The cell lines with chromosome 16 LOH can be used for screening candidate tumor suppressor genes at 16q in breast cancer.

Entities:  

Mesh:

Year:  2002        PMID: 11890994     DOI: 10.1016/s0165-4608(01)00565-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  Infrequent mutation of ATBF1 in human breast cancer.

Authors:  Xiaodong Sun; Yingfa Zhou; Kristen B Otto; Mingrong Wang; Ceshi Chen; Wei Zhou; Krithika Subramanian; Paula M Vertino; Jin-Tang Dong
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-24       Impact factor: 4.553

2.  Nuclear matrix-associated protein SMAR1 regulates alternative splicing via HDAC6-mediated deacetylation of Sam68.

Authors:  Kiran Kumar Nakka; Nidhi Chaudhary; Shruti Joshi; Jyotsna Bhat; Kulwant Singh; Subhrangsu Chatterjee; Renu Malhotra; Abhijit De; Manas Kumar Santra; F Jeffrey Dilworth; Samit Chattopadhyay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

3.  Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions.

Authors:  Brian J Miller; Daolong Wang; Ralf Krahe; Fred A Wright
Journal:  Am J Hum Genet       Date:  2003-09-16       Impact factor: 11.025

4.  Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.

Authors:  John Brognard; Matthew Niederst; Gloria Reyes; Noel Warfel; Alexandra C Newton
Journal:  J Biol Chem       Date:  2009-03-26       Impact factor: 5.157

5.  The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas.

Authors:  L Li; J Ying; H Li; Y Zhang; X Shu; Y Fan; J Tan; Y Cao; S W Tsao; G Srivastava; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

6.  Expression analysis of candidate breast tumour suppressor genes on chromosome 16q.

Authors:  Tom van Wezel; Marcel Lombaerts; Eddy H van Roon; Katja Philippo; Hans J Baelde; Karoly Szuhai; Cees J Cornelisse; Anne-Marie Cleton-Jansen
Journal:  Breast Cancer Res       Date:  2005-10-18       Impact factor: 6.466

7.  SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression.

Authors:  Aftab Alam; Nandaraj Taye; Sonal Patel; Milind Thube; Jayati Mullick; Vibhuti Kumar Shah; Richa Pant; Tanaya Roychowdhury; Nilanjan Banerjee; Subhrangsu Chatterjee; Rittwika Bhattacharya; Rini Roy; Ashis Mukhopadhyay; Devraj Mogare; Samit Chattopadhyay
Journal:  Neoplasia       Date:  2019-08-15       Impact factor: 5.715

8.  Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1.

Authors:  Arpankumar Choksi; Apoorva Parulekar; Richa Pant; Vibhuti Kumar Shah; Ramakrishna Nimma; Priyanka Firmal; Smriti Singh; Gopal C Kundu; Sanjeev Shukla; Samit Chattopadhyay
Journal:  Cancer Metab       Date:  2021-04-16

9.  Aberrant CBFA2T3B gene promoter methylation in breast tumors.

Authors:  Anthony J Bais; Alison E Gardner; Olivia L D McKenzie; David F Callen; Grant R Sutherland; Gabriel Kremmidiotis
Journal:  Mol Cancer       Date:  2004-08-10       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.